Focus:
M&As
-
25 June 2020
Novo Nordisk moves further into CV diseases with Corvidia acquisition
Cardio-renal specialist Corvidia Therapeutics has been acquired for $725m by diabetes giant Novo Nordisk. This deal builds on Novo Nordisk’s recent move into the CV space through outcomes trials of...
-
12 May 2020
AbbVie acquires Allergan: unpicking the year-long approval process
AbbVie’s $63bn acquisition of Allergan has been in the works since June 2019. It aims to diversify AbbVie’s portfolio beyond its blockbuster product Humira and create cost efficiencies in R&D...
-
21 April 2020
Asia-Pacific witnesses 5.4% increase in deal activity during week ended 19 April 2020
Data and analytics company GlobalData has revealed that deal activity in the Asia-Pacific region has shown signs of revival during the week ended 19 April 2020.
-
16 April 2020
Global deal activity decreases 17.2% with 899 deals last week
A total of 899 deals were announced globally during the week ended 12 April 2020, registering a 17.2% drop when compared to 1,086 deals announced during the previous week, according...
-
9 April 2020
Healthcare sector sees growth in deal activity for second consecutive week
The deal activity in the global healthcare sector, including pharmaceuticals and medical equipment, has witnessed second consecutive week of growth, according to GlobalData’s deals database. The number of deals increased...
-
3 April 2020
Covid-19 impact: Global VC funding activity continues to remain subdued
The number of venture capital (VC) funding announced deals dropped by 22.5% during the week ended 29 March 2020 compared to the previous week, according to GlobalData’s deals database. VC...
-
3 April 2020
Healthcare sector witnesses growth in deal activity despite Covid-19 concerns
A total of 152 deals were announced in the global healthcare sector, including pharmaceuticals and medical equipment, during the week ended 29 March 2020 according to GlobalData’s deals database. The...
-
4 September 2019
Vertex-Semma $950m acquisition: bringing diabetes into the pipeline
Vertex Pharmaceutics has announced it has entered into a definitive agreement to acquire Semma Therapeutics for $950m. Semma is an early-stage biotech that is developing stem cell therapies for type...
-
2 September 2019
Takeda-Shire deal: the strategy behind Japan’s largest foreign acquisition
Within a year of Japan’s Takeda expressing its interest in buying Shire, the deal had been approved by all necessary regulatory authorities and both companies’ shareholders; allowing Shire’s integration into...
-
23 August 2019
US pharma industry sees a drop of 22.2% in deal activity in July 2019
The US pharma industry saw a drop of 22.2% in overall deal activity during July 2019, when compared with the last 12-month average, according to GlobalData's deals database. Embed this...